CytoDyn Shareholders Shown HIV/AIDS Breakthrough.

LOS ANGELES -- Shareholders attending the 2005 Annual Meeting of CytoDyn, Inc. (OTCBB:CYDY) in Los Angeles, Calif., were treated to a multimedia scientific presentation by Dr. Glenn Morrison, Director of Clinical Development for Symbion Research International, CytoDyn's CRO. The report by Dr. Morrison detailed the human experience to date for Cytolin(R), the Company's targeted immune therapy for treating HIV/AIDS.

In addition to providing preliminary evidence for safety and efficacy, results from these FDA-sanctioned in vivo experiments included some provocative data that could sharpen our understanding of the human immune system. Cytolin(R) is the first targeted immune therapy for HIV/AIDS that was shown to significantly reduce viral burden in preliminary human studies. The potential advantage is that Cytolin(R) exerts its effect on the immune system and not the virus. As a result, a species of virus resistant to the effects of Cytolin(R) cannot emerge through natural selection because the drug has no effects on the virus itself.

In addition to providing an additional treatment for the disease, Cytolin(R) might extend the useful life of the antiretroviral drugs currently used to treat HIV/AIDS, such as Emtriva(R) and Truvada(R) manufactured by Gilead (Nasdaq:GILD), Epzicom(R) and Lexiva(R) manufactured by GlaxoSmithKline (NYSE:GSK) and Reyataz(R) and Zerit(R) manufactured by Bristol-Myers Squibb (NYSE:BMY) to name a few. If, for instance, random mutation in an infected host produced a species of HIV that was resistant to the protease inhibitors, then the host's immune system might suppress that species if Cytolin(R) were used as an adjunctive therapy. If so, then the host would not wind up being colonized by a species of virus resistant to the protease inhibitors.